TORONTO and BENGALURU, India, Oct. 23, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON), today ...
BRIDGEWATER, N.J. and BENGALURU, India, Feb. 24, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: ...
Yesintek, a Stelara biosimilar, received FDA approval for IBD, plaque psoriasis, and psoriatic arthritis, with a launch expected in late 2025. Clinical trials confirmed Yesintek's equivalence to ...
Biocon Biologics has secured multiple market access agreements for Yesintek (ustekinumab-kfce), its biosimilar to Stelara (ustekinumab). The market access agreements from numerous plans represent more ...
New Delhi: Biocon Ltd on Monday said its arm Biocon Biologics Ltd has secured multiple market access agreements in the US for its biosimlar, Yesintek, that has been approved for the treatment of Crohn ...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon announced that Health Canada has granted a Notice of Compliance (NOC) for Yesintek (ustekinumab ...
Hosted on MSN
Biocon's biologics arm gets Health Canada approval for monoclonal antibody drug Yesintek
Mumbai, Oct. 23 -- Yesintek is ustekinumab injection and Yesintek I.V. is ustekinumab for injection, solution for intravenous infusion. These drugs are biosimilars of Stelara (ustekinumab injection) ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved the Stelara biosimilar Yesintek for indications matching the reference product, with a ...
Biocon Biologics, a biosimilars company and subsidiary of Biocon Ltd, secured multiple market access agreements for Yesintek, a biosimilar to Stelara, used for the treatment of common chronic ...
Please provide your email address to receive an email when new articles are posted on . Four biosimilars for Stelara have launched in the United States this year following legal settlements with the ...
The US Food and Drug Administration (FDA) has approved ustekinumab-kfce (Yesintek) as a biosimilar to ustekinumab (Stelara) for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results